Modified mRNA-LNP Vaccines Confer Protection against Experimental DENV-2 Infection in Mice
In: Molecular Therapy - Methods & Clinical Development, Jg. 18 (2020-09-01), S. 702-712
Online
unknown
Zugriff:
Dengue virus (DENV) infection is a major global public health concern, and there is no effective vaccine for it. In this study, we describe the design and characterization of three nucleotide-modified mRNA vaccines (prME-mRNA, E80-mRNA, and NS1-mRNA) for DENV-2. Our results showed that vaccination with E80-mRNA alone or a combination of E80-mRNA and NS1-mRNA can induce high levels of neutralizing antibodies and antigen-specific T cell responses; furthermore, these vaccines confer complete protection against DENV-2 challenge in immunocompetent mice. These data provide foundations for further development of a tetravalent DENV vaccine based on nucleotide-modified mRNA.
Graphical Abstract
Dengue virus (DENV) infection is a major public health concern for which the current vaccine is not satisfactory. Zhang et al. developed new mRNA vaccines for DENV-2 that confer complete protection against viral challenge in mice. These data provide foundations for further development of a tetravalent DENV mRNA vaccine.
| Titel: |
Modified mRNA-LNP Vaccines Confer Protection against Experimental DENV-2 Infection in Mice
|
|---|---|
| Autor/in / Beteiligte Person: | Li, Min ; Zhang, Mengling ; Jin, Xia ; Sun, Jin |
| Link: | |
| Zeitschrift: | Molecular Therapy - Methods & Clinical Development, Jg. 18 (2020-09-01), S. 702-712 |
| Veröffentlichung: | Elsevier BV, 2020 |
| Medientyp: | unknown |
| ISSN: | 2329-0501 (print) |
| DOI: | 10.1016/j.omtm.2020.07.013 |
| Schlagwort: |
|
| Sonstiges: |
|